Journal
FUNDAMENTAL & CLINICAL PHARMACOLOGY
Volume 30, Issue 6, Pages 616-624Publisher
WILEY
DOI: 10.1111/fcp.12214
Keywords
databases; electronic healthcare records; France; pharmacoepidemiology; SNIIRAM
Categories
Funding
- National Research Agency (ANR: Agence Nationale de la Recherche) [ANR-11-PHUC-001]
Ask authors/readers for more resources
In this study, we aimed to provide an updated overview of drug data contained in the French health insurance database (SNIIRAM) and its associated national representative sample (EGB). This study identified most common problems concerning drug data: (i) change in level of coverage of drugs of interest (drug no more eligible for reimbursement or no more prescription-only), (ii) break in patients' eligibility (in connection with change of healthcare plan or patients' identifier), and (iii) technical and regulatory issues. We provide a brief checklist to enable a structured identification of these issues. The impact of gap in drug data availability on study validity will depend on the research question, drug, setting, and population of interest. The French health insurance database and associated sample are valuable resources for pharmacoepidemiological research. There is a need to pursue further methodological and validation studies to promote accurate and transparent use of French health insurance databases for pharmacoepidemiology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available